特发性血小板减少性紫癜是一种自身免疫性疾病,抗血小板抗体引起血小板破坏而导致严重的出血。常规的治疗是使用糖皮质激素、免疫抑制剂、抗人CD20单克隆抗体或脾切除,但引起复发或者许多不良反应。最近的研究显示:血小板生成素是能调节血小板产生的细胞因子,艾曲波帕为小分子口服非肽血小板生成素激动剂,能刺激血小板生成素受体,引起巨核细胞分化,血小板生成。本文介绍艾曲波帕的作用机制、药效学、药动学和临床评价。 Idiopathic thrombocytopenic purpura is an autoimmune disease that causes severe bleeding due to platelet destruction caused by anti-platelet antibodies. Conventional treatment is the use of glucocorticoids, immunosuppressive agents, anti-human CD20 monoclonal antibodies or splenectomy, but causes recurrent or many adverse reactions. Recent studies have shown that thrombopoietin is a cytokine that modulates platelet production. Elcuoban is a small molecule oral non-peptide thrombopoietin agonist that stimulates platelet-derived receptors and causes megakaryocyte differentiation and platelet production. This article describes the mechanism of action of eltrombopag, pharmacodynamics, pharmacokinetics and clinical evaluation.